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ABSTRACT
The Sneddon’s syndrome is a rare disorder characterized by the 
occurrence of cerebrovascular disease associated with livedo 
reticularis. The antiphospholipid syndrome is the most frequent type 
of acquired thrombophilia, defined by the occurrence of thrombosis 
or pregnancy morbidity in the presence of persistently positive 
antiphospholipid antibodies. Approximately 80% of Sneddon’s 
syndrome patients have an antiphospholipid antibody marker. These 
antibodies may play a pathogenetic role in some cases of Sneddon’s 
syndrome, and many authors consider these two syndromes as the 
same entity. Although clinical features of antiphospholipid syndrome 
and Sneddon’s syndrome may overlap, there is a distinction between 
clinical and laboratory evidence suggesting that these two entities 
are different diseases. A recent finding of coagulopathies, including 
elevated levels of coagulation factor VII, decreased levels of 
protein S, and activated protein C in Sneddon’s syndrome patients 
suggested a possible biological link between the vasculopathy and 
a primary coagulopathy. Moreover, the clinical course seems to be 
progressive in Sneddon’s syndrome patients and includes increase 
of disability and cognitive deterioration, more arterial involvement, 
and the antiphospholipid syndrome shows a more benign course. 
Both syndromes share clinical and laboratory features, and whether 
Sneddon’s syndrome represents a spectrum of antiphospholipid 
syndrome remains unclear. Sneddon’s syndrome patients have a 
worse prognosis and may represent a subgroup of patients who 
demands more rigorous follow-up. It is important to recognize the 
Sneddon’s syndrome, particularly because stroke episodes may be 
prevented through appropriate treatment. 
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RESUMO
A síndrome de Sneddon é um distúrbio raro caracterizado 
pela ocorrência de doença cerebrovascular associada a livedo 
reticular. A síndrome do anticorpo antifosfolipídio é o tipo mais 
frequente de trombofilia, definida pela ocorrência de trombose ou 
morbidade gestacional na presença de anticorpos antifosfolípides 
persistentemente positivos. Aproximadamente 80% dos pacientes 
com síndrome de Sneddon apresentam um marcador de anticorpo 
antifosfolipídio. Esses anticorpos podem exercer um papel 
fisiopatológico em alguns casos de síndrome de Sneddon, e muitos 
autores consideram essa síndrome e a síndrome do anticorpo 
antifosfolipídio a mesma entidade. Apesar de os quadros clínicos 
das suas síndromes poderem se sobrepor, há evidência clínica 
e laboratorial distintiva, sugerindo que as duas entidades são 
doenças diferentes. Um achado recente de coagulopatia, incluindo 
níveis elevados do fator VII de coagulação, diminuição dos níveis 
da proteína S, e proteína C ativada em pacientes com síndrome 
de Sneddon, sugeriu uma possível ligação biológica entre a 
vasculopatia e coagulopatia primária. Além disso, o curso clínico 
pareceu ser progressivo em pacientes com síndrome de Sneddon, 
visto que há aumento de incapacidade e deterioração cognitiva, 
além de maior envolvimento arterial, enquanto a síndrome do 
anticorpo antifosfolipídio apresenta um curso mais benigno. Ambas 
as síndromes compartilham características clínicas e laboratoriais; 
até qual ponto a síndrome de Sneddon representa um espectro da 
síndrome do anticorpo antifosfolipídio permanece desconhecido. Os 
pacientes com a primeira síndrome apresentam pior prognóstico 
e podem representar um subgrupo de pacientes que requer um 
seguimento mais rigoroso. É importante reconhecer a síndrome de 
Sneddon já que os episódios de acidente vascular cerebral podem 
ser prevenidos com a terapia apropriada. 
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INTRODUCTION 
Sneddon’s syndrome (SS) is a rare disorder 
characterized by the occurrence of cerebrovascular 
disease like stroke or transitory ischemic attack 
associated with livedo reticularis(1). Patients may have 
positive antiphospholipids (aPLs) antibodies and 
other manifestations of primary antiphospholipid 
syndrome (APS). We report a case of SS, and discuss 
its relation with APS. 
CASE REPORT
A 41-year-old woman was referred to neurologic 
evaluation due to recurrent episodes of paresthesia 
in upper limbs for the last 20 years, lengthening for 
20 minutes each episode. Twenty months before she 
presented an abrupt dysarthria and right hemiparesis 
that did not recover. At that time she was admitted 
for investigation. The patient developed arterial 
obstruction on her left foot two years before, which 
made her fourth toe turns blue and numb. She 
smoked for twenty years, had two first-trimester 
miscarriages and was receiving enalapril 10mg per day 
for hypertension. The patient denied any episodes of 
thrombosis, photosensibility, arthralgias, malar rash or 
oral ulcers. 
General examination showed livedo reticularis 
involving abdominal region and upper limbs (Figure 1) 
and normal pulmonary and cardiac auscultation. A 
cold blue fourth pododactile was evident. Neurological 
examination revealed mild proportionate right 
hemiparesis with hyperreflexia and preserved sensory 
functions. Brain magnetic resonance imaging disclosed 
multiple white-matter abnormalities at frontal cortico-
subcortical region suggesting involvement of small-
vessels (Figure 2). Spinal fluid analysis showed elevated 
protein (64mg/dL) and transthoracic echocardiography, 
mild left atrial enlargement, thickening of the mitral 
valve with discrete reflux. The anticardiolipin antibodies 
(aCL) and the lupic anticoagulant were negative.
Figure 1. Livedo reticularis involving the abdominal region
Figure 2. Magnetic Resonance (FLAIR) disclosed multiple white-matter 
abnormalities at frontal cortico-subcortical region
The patient was diagnosed as SS, and after three 
months of follow-up showed elevated IgM aCL titers 
that remained positive for 6 months. She was treated 
with oral anticoagulation.
DISCUSSION
APS is the most frequent type of acquired thrombophilia, 
defined by the occurrence of thrombosis or pregnancy 
morbidity in the presence of persistently positive aPL 
antibodies(2,3). Three aPL antibodies may be found in 
APS: aCL (60 to 70%), lupus anticoagulant (20 to 30%) 
and beta2-glycoprotein (5 to 10%). The aPLs antibodies 
promote activation of endothelial cells, monocytes, 
and platelets; and overproduction of tissue factor and 
thromboxane A2. Complement activation might have a 
central pathogenetic role(2). 
The estimated annual incidence of SS is four cases 
per million and its precise etiology is unknown(1). The 
cardinal manifestation of livedo reticularis results 
from thrombosis of subcutaneous arterioles and 
compensatory capillary dilation that causes blood to 
stagnate, which on the other hand causes mottled 
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discoloration(3).Histopathological analysis revealed a 
non-inflammatory thrombotic vasculopathy of the small 
and medium arteries of skin and brain(1,4). 
Approximately 41% of SS present aCL antibodies(4). 
When other aPL antibodies were evaluated, such 
as anti-protrombin, lupus anticoagulant and anti-
phosphatidilethanolamine, almost 80% of SS patients 
had an aPL marker(1,5,6). However, in many cases 
no antibodies could be found(7). These antibodies 
may play a pathogenetic role in some cases of SS. In 
addition, some authors consider SS and APS as the 
same entity(3,4,6,8).
Besides autoimmunity markers, SS and APS share 
clinical manifestations such as headache, hypertension, 
vascular dementia, involvement of cardiac valves and 
kidneys. Recurrent miscarriages and thrombosis could 
also be found in SS without aPL antibodies(1,4,8). Other 
dermatological manifestations include acrocyanosis, 
Raynaud’s phenomenon and, less frequently, circumscribed 
skin necrosis(8).
It is important to determine the occurrence of 
cardiac manifestations in APS and SS patients. Studies 
suggest that valvulopathy might be a source for emboli 
and a possible cause of ischemic stroke. Also, there is an 
association between valvular heart disease and several 
central nervous disease manifestations in aPL positive 
patients, not only regarding stroke and transient ischemic 
attack(3).
Although clinical features of APS and SS may 
overlap, there is distinctive clinical and laboratory 
evidence suggesting that these two entities are different 
diseases(5). Several associated coagulopathies, including 
elevated levels of coagulation factor VII, decreased 
levels of protein S, and activated protein C resistance 
have been observed, suggesting a possible biological link 
between the vasculopathy and a primary coagulopathy 
in SS(3,8). Moreover, the clinical course seems to be 
progressive in SS patients and includes increase of 
disability and cognitive deterioration, more arterial 
involvement. APS shows a more benign course(4). 
Despite abnormalities in thrombotic mechanisms 
have been described, they have not been confirmed in 
large series, and the presence of aPL remains the most 
reliable explanation for the thrombotic process, but it 
accounts only for a subset of SS patients(8).
Considering secondary thromboprophylaxis, the 
main treatment for APS patients is anticoagulation 
rather than immunosuppression(2,3). For SS patients 
with aPL antibodies warfarin is often used(1,5). On the 
other hand, one study demonstrated that SS patients 
without aPL benefit from antiplatelet therapy(9).
Our patient had livedo reticularis, pregnancy 
morbidity, cardiac valvular disorder and probably 
arterial thrombosis in inferior limbs, which are 
commonly associated to both disorders. In the light 
of information exposed, she was diagnosed as SS 
with positive aPL antibodies, therefore requiring 
anticoagulation. 
In conclusion, the SS and the APS share clinical 
and laboratory features, and whether SS represents 
a spectrum of APS remains unclear. SS patients have 
a worse prognosis and may represent a subgroup of 
patients who demands more rigorous follow-up. It is 
important to recognize the SS, particularly because 
stroke episodes may be prevented through appropriate 
treatment. 
REFERENCES
1. Aladdin Y, Hamadeh M, Butcher K. The Sneddon syndrome. Arch Neurol. 
2008;65(6):834-5.
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid 
syndrome. Lancet. 2010;376(9751):1498-509.
3. Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid 
(Hughes) syndrome. Rheum Dis Clin N Am. 2006;32(3):465-90.
4. Fetoni V, Grisoli M, Salmaggi A, Carriero R, Girotti F. Clinical and neuroradiological 
aspects of Sneddon’s syndrome and primary antiphospholipid antibody 
syndrome. A follow-up study. Neurol Sci. 2000;21(3):157-64.
5. Caldas CA, de Carvalho JF. Primary antiphospholipid syndrome with and 
without Sneddon’s syndrome. Rheumatol Int. 2011;31(2):197-200.
6. Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J. 
Antibodies to prothrombin in patients with Sneddon’s syndrome. Neurology. 
1999;53(1):223-5.
7. Francès C, Piette JC. The mystery of Sneddon Syndrome: relationship with 
antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun. 
2000;15(2):139-43.
8. Kalashnikova LA, Aleksandrova EN, Novikov AA, Dobrynina LA, Nasonov EL, 
Sergeeva EV, et al. [Anti-phosphatidylethanolamine antibodies in patients 
with Sneddon’s syndrome]. Klin Med (Mosk). 2005;83(5):46-9. Russian.
9. Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon 
syndrome with or without antiphospholipid antibodies. A comparative study 
in 46 patients. Medicine (Baltimore). 1999;78(4):209-19.
